Enbrel (etanercept) is a biologic medication that works by blocking a protein called tumor necrosis factor (TNF), which drives inflammation in conditions like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. Most people tolerate it well, but it carries a range of possible side effects, from mild injection site soreness to rare but serious risks involving the immune system. Here’s what to expect.
Injection Site Reactions
The most common side effect is a reaction at the injection site: redness, swelling, itching, or mild pain where the needle goes in. These reactions typically last 3 to 5 days and tend to become less frequent over the first few months of treatment. They’re rarely severe enough to require any intervention.
A few things can make injections more comfortable. Letting the prefilled syringe or dose tray sit at room temperature for 15 to 30 minutes before injecting reduces the sting of cold medication. If you use the AutoTouch reusable autoinjector, it lets you choose between three injection speeds so you can find the one that feels best. Rotating injection sites (thigh, abdomen, upper arm) also helps prevent soreness from building up in one area.
Infections: The Biggest Concern
Because Enbrel suppresses part of your immune system, it increases your vulnerability to infections. This is the risk the FDA considers serious enough to flag in a boxed warning, the strongest safety alert placed on a medication label. Most of these infections are ordinary ones, like upper respiratory infections, sinus infections, or urinary tract infections, that may just hit harder or linger longer than usual.
The more dangerous infections are rarer but important to know about. They include:
- Tuberculosis (TB), including reactivation of a latent infection you may not know you carry. TB in people on Enbrel often spreads beyond the lungs, making it harder to detect and treat. You’ll be tested for latent TB before starting treatment and may be tested periodically afterward.
- Invasive fungal infections, such as histoplasmosis, coccidioidomycosis, and others. These are more common in certain geographic regions (the Ohio and Mississippi River valleys for histoplasmosis, the southwestern U.S. for coccidioidomycosis) and can present as widespread illness rather than a localized lung infection.
- Opportunistic bacterial and viral infections, including Legionella and Listeria, which rarely cause serious illness in people with normal immune function.
The practical takeaway is to pay attention to signs of infection that feel unusual: fevers that won’t break, a cough that worsens over weeks, unexplained weight loss, or night sweats. These warrant a prompt call to your doctor, because catching these infections early makes a significant difference in outcomes.
Cancer Risk
The FDA label carries a warning about potential malignancy risk with TNF blockers, particularly lymphoma. This warning exists partly because early case reports raised concern and partly because autoimmune diseases like rheumatoid arthritis already carry a higher baseline lymphoma risk, making it difficult to separate the effect of the drug from the effect of the disease.
A large surveillance study tracked cancer rates in rheumatoid arthritis patients on TNF inhibitors over six years. The findings were reassuring: cancer risk was not increased compared to patients who had never taken a biologic. The overall incidence rate for all cancers stayed constant over time on the medication, with no difference when researchers broke the data down by age, gender, or duration of treatment. Patients on etanercept specifically had a slightly lower cancer rate during their first year of treatment compared to biologic-naive patients, and rates were similar to the comparison group after that.
That said, the theoretical risk hasn’t been fully ruled out with longer use, which is why the warning remains on the label. Skin cancers, both melanoma and non-melanoma types, have been reported in patients on TNF blockers, so regular skin checks are a reasonable precaution.
Nervous System Effects
Rare but serious neurological problems have been reported in people taking Enbrel. These include demyelinating diseases, a category of conditions where the protective coating around nerve fibers breaks down. Multiple sclerosis is the most well-known example, but optic neuritis (inflammation of the nerve connecting the eye to the brain) and Guillain-Barré syndrome (a condition where the immune system attacks peripheral nerves, causing weakness) have also been reported.
If you already have a demyelinating condition or a history of seizures, Enbrel may worsen it. New-onset numbness, tingling, vision changes, or unusual muscle weakness while on the medication are symptoms worth reporting immediately. These events are uncommon, but they don’t always resolve after stopping the drug, which is why early recognition matters.
Heart Failure Considerations
TNF blockers as a class carry warnings about worsening heart failure or triggering new-onset heart failure. Interestingly, the data on Enbrel specifically is more nuanced than the warning might suggest. A clinical trial in patients with advanced heart failure (NYHA class III to IV) found that etanercept was safe, well tolerated, and actually led to improvements in heart pumping function and heart structure over three months. There were no significant changes in heart rate, blood pressure, or blood test results compared to placebo.
Still, if you have existing heart failure, your doctor will monitor you closely. The broader concern with TNF blockers and heart failure comes primarily from trials of a different TNF blocker (infliximab) at high doses, but the class-wide warning applies to Enbrel as well.
Autoimmune Reactions
Paradoxically, a drug designed to treat autoimmune disease can sometimes trigger new autoimmune responses. Some patients on Enbrel develop positive antinuclear antibodies (ANA), which are markers the immune system is becoming more reactive. In most cases this is a lab finding with no symptoms, but in rare instances it can progress to a lupus-like syndrome. Reported symptoms include fever, chest pain from inflammation around the heart or lungs, low blood cell counts, and blood in the urine. These symptoms typically resolve after stopping the medication.
Blood Cell Changes
Enbrel can, in rare cases, affect blood cell production. The most serious version of this is pancytopenia, where red blood cells, white blood cells, and platelets all drop simultaneously, or aplastic anemia, where the bone marrow stops producing enough new blood cells. These are uncommon but potentially dangerous, which is why your doctor may order periodic blood tests during treatment. Unusual bruising, persistent fatigue, or frequent infections that seem out of proportion to your usual experience could signal a blood count problem.
Other Common Side Effects
Beyond injection reactions, people on Enbrel commonly report headaches and upper respiratory symptoms like a runny nose, sore throat, or cough. These tend to be mild and are often indistinguishable from seasonal colds. Nausea, abdominal pain, and rash have also been reported, though less frequently. For most people, these side effects are manageable and don’t require stopping treatment.
The pattern with Enbrel side effects follows a general rule: the common ones are mild, and the serious ones are rare. Most people stay on the medication for years without major issues, but knowing what to watch for helps you catch the uncommon problems early, when they’re most treatable.